G1 Therapeutics, Inc. (GTHX) Tops Q2 EPS by 7c, reaffirms guidance

G1 Therapeutics, Inc. (NASDAQ: GTHX) reported Q2 EPS of ($0.10), $0.07 better than the analyst estimate of ($0.17). Revenue for the quarter came in at $16.55 million versus the consensus estimate of $16.26 million.

2024 Financial Guidance

G1 today reaffirmed its full year 2024 revenue guidance. G1's guidance is based on current expectations for continued sales growth of COSELA in the U.S. and achievement of its forecasts. The Company expects to generate between $60 million and $70 million in COSELA net revenue in 2024. Additionally, G1 expects its full year 2024 operational expenses to be 25% to 30% below that of the prior year. As a result, G1 believes it has sufficient cash runway to achieve anticipated company profitability in the second half of 2025.

For earnings history and earnings-related data on G1 Therapeutics, Inc. (GTHX) click here.

You May Also Be Interested In

• Movano (MOVE) Misses Q2 EPS by 195c
• HeartCore Enterprises, Inc. (HTCR) Misses Q2 EPS by 185c
• Hydrofarm Holdings Group, Inc. (HYFM) Misses Q2 EPS by 134c